Jiangsu, China

Sishun Kang

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 13.8

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2018-2022

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Sishun Kang: Innovator in Pharmaceutical Chemistry

Introduction

Sishun Kang is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 4 patents to his name, Kang's work focuses on innovative solutions for treating various clinical conditions.

Latest Patents

Kang's latest patents include groundbreaking research on 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors. This patent discloses compounds that have the potential to inhibit the PARP enzyme, which plays a crucial role in DNA repair mechanisms. Additionally, he has developed N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors. These compounds are designed to target the hedgehog signaling pathway, which is implicated in several types of cancer. The invention may provide new avenues for treating conditions responsive to hedgehog activity inhibition.

Career Highlights

Sishun Kang is currently associated with Impact Therapeutics, Inc., where he continues to advance his research in pharmaceutical innovations. His work has garnered attention for its potential impact on cancer treatment and other medical applications.

Collaborations

Kang collaborates with notable colleagues, including Ye Edward Tian and Feng Yin, who contribute to his research endeavors and help drive innovation within the company.

Conclusion

Sishun Kang's contributions to pharmaceutical chemistry exemplify the importance of innovation in developing new therapeutic agents. His patents reflect a commitment to addressing critical health challenges through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…